Optho Remedies P Ltd with 40 years of strong in ophthalmic manufacturing & marketing. Optho Has a strong and sturdy team across the length & breath of the country.
Post: Product Executive
A new technique to produce cells with insulin-secretion capabilities has been developed, according to research presented at the 54th Annual European Society for Paediatric Endocrinology Meeting. The technique could be further developed to be used in the transplantation for patients with type 1 diabetes.
European Commission (EC) has granted marketing authorization for Praluent® (alirocumab) for the treatment of bad cholesterol, known as low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia. Praluent is the only EC-approved PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor that is available in two starting doses as a single 1-milliter (mL) injection (75 mg and 150 mg) once every two weeks, offering two levels of efficacy. Praluent will be available in a single-dose pre-filled pen that patients self-administer.